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The rise in multidrug-resistant tuberculosis means that new 
drugs and new drug combinations are needed to address the 
problems associated with current treatments. Drug 
screening facilities aim to identify new high quality drug 
compounds, or novel drug combinations, for treatment of 
tuberculosis. The experimental drug assay procedure 
produces multivariate data that is difficult to analyse and 
onerous to process in order to determine which drug 
combinations should be pursued for further development.  
In this design study, we have developed a visualization tool 
to assist with analysis and processing of this 
multidimensional data. The tool was developed with an 
iterative user-centred design process, beginning with a low 
fidelity paper mock-up through to the deployment of a fully 
functional, computer-based prototype that expert users 
judge to be both usable and effective.    
CCS Concepts 
• Human-centered computing→Scientific 
visualization   • Human-centered computing→User centered 
design 
Keywords 
visualization; Tuberculosis; drug screening assay; user-centred 
design; design study. 
1. INTRODUCTION 
A design study has been defined as “project in which visualization 
researchers analyze a specific real-world problem faced by 
domain experts, design a visualization system that supports 
solving this problem, validate the design, and reflect about 
lessons learned in order to refine visualization design guidelines” 
[8]. Our design study described here aims to develop a data 
visualization that will aid drug discovery teams in identifying the 
most promising active drug combinations against drug-resistant 
tuberculosis.  
Tuberculosis (TB) is caused by Mycobacterium tuberculosis and 
kills approximately 1.5 million people annually [1]. Further, about 
a third of the world’s population is infected with latent TB [2]. 
The rise in multidrug-resistant TB means that new drugs and new 
drug combinations are needed to address the problems associated 
with current treatments [2].  
TB drug screening facilities, such as the Molecular 
Mycobacteriology Research Unit (MMRU) at the University of 
Cape Town, aim to identify new high quality drug compounds, or 
novel drug combinations, which inhibit the growth of M. 
Tuberculosis. The screening process uses 96-well microplate 
assays to measure drug potency and efficacy. Three-drug 
combinations are tested using five assay plates per experiment, a 
procedure which produces a three-dimensional array of drug 
interactions.  
 
Each assay experiment places candidate drugs at varying 
concentrations across wells in the microtitre plate. A constant 
volume of stained bacteria is added to each well. After a defined 
period, the microplate reader measures the absorbance/luminosity 
for each well. High absorbance values indicate thriving bacteria 
and hence an ineffective combination. Conversely, a low 
absorbance value indicates few bacteria remaining, suggesting 
successful growth inhibition and an effective drug combination. 
Drug concentration values and luminosity/absorbance values are 
used to determine drug potency, efficacy and drug-drug 
interactions by calculation of the Minimum Inhibitory 
Concentration (MIC) and Fractional Inhibitory Concentration 
Index (FIC index) values for each well. The MIC is the minimum 
concentration of a drug, when acting alone, required to inhibit the 
growth of bacteria. A concentration lower than this value results 
in unsuccessful inhibition, one higher prevents bacteria growth. 
Consideration of the drug concentration is important for avoiding 
toxicity in human treatment: ideal drugs inhibit bacterial growth at 
low concentrations.  The FIC index is a linear sum of the drug 
concentrations weighted according to the MIC, when two or more 
drugs are in combination. The FIC index value represents the type 
of drug interaction: synergistic, antagonistic, no effect or additive.   
A drug screen thus ultimately produces a 5-tuple data set 
comprising: drug concentration, luminosity/absorbance, Minimum 
Inhibitory Concentration (MIC), Fractional Inhibitory 
Concentration Index (FIC index) and percentage inhibition.  
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For three-drug combination assays, the resultant 5-tuple 3D data 
set is difficult and time consuming to analyse and explore. To our 
knowledge, there are no existing visualization tools that focus on 
the display of microplate data, let alone three-drug combination 
assays:  TB researchers currently plot and compare the 2D data 
from individual microplate assays using Microsoft Excel. An 
effective visualization of microplate data that leverages the ability 
of the human visual system to rapidly detect and identify patterns 
has the potential to accelerate analysis [3]. Developing a scientific 
visualization that is both effective and usable to the users is a form 
of problem-driven research that entails interaction with domain 
experts to design a satisfactory solution. The design study 
described here comprises a contextual enquiry followed by a 
cyclic user-centred design process: working in consultation with a 
researcher, we built from a paper-prototype, and iterated to a fully 
functional implementation of our final visualization design. 
 
2. METHODOLOGY 
2.1 Visualization design guidelines.  
An effective data visualization acts as a cognitive tool, facilitating 
understanding of, and reasoning about, data.  The design phases 
in this study were informed by the visual analytics mantra 
adapted from Schneiderman [10]: analyse first, show the 
important; zoom, filter and analyse further; details on demand 
[11]. This mantra establishes that the user initially has an 
overview of the data, then identifies regions or patterns of interest 
and only, if they wish to, then analyses further and accesses the 
details of the data.  This ensures that there is no information 
overload at any time and exemplifies the need for user–system 
interaction: an overview of the data is presented and additional 
data can be requested through interaction with the system. This is 
particularly important for multivariate data, which gives rise to 
unique challenges in designing an effective visualization. For 
example, care must be taken when mapping data attributes to 
graphics to avoid overwhelming the observer’s viewing ability. 
Too much detail at once increases the difficulty of distinguishing 
relevant and irrelevant information. Good designs maximize the 
use of space and intelligently structure space. Further, interaction 
techniques play a key role in determining the effectiveness of a 
visualization [19]: the use of consistent usable interaction design 
models with clear visual feedback is essential.  Data 
representation without interaction is merely a static image: in 
order for visualizations to be a means of cognitive support, they 
must allow for manipulation and data exploration [14].  
 
The primary objective of the visualization tool is to aid in 
identifying the drug combinations that are most promising, a 
process which cannot be done by merely looking at the assay plate 
images. The researchers would like to directly elucidate the dose 
(drug concentrations)-response (inhibition/potency) relationship 
and identify regions of significant synergy/antagonism. The 
specific design goals for the visualization module were identified 
in collaboration with by Charles Omollo – a PHD student in the 
MMRU specializing in TB Drug Research using three drug 
combinations and thus an expert user of the system. The high-
level analysis process requirements for the tool were identified as:  
• an accurate and clear representation of the well plates, which 
displays the number of wells in which all three drugs  work 
together, including both synergistic and antagonistic 
interactions;  
• the ability to select a plate of interest to view in more detail;  
• the ability to view interaction type, FIC and % inhibition for 
a well.   
Key requirements were that visualization must provide a faithful 
representation of the raw data to prevent inaccurate observations 
and that the output must be able to be mapped onto the 
visualization of the plates. 
 
2.2 Design Study Methodology  
As a standard procedure for the analysis of three-drug 
experiments could not be found in literature, experts in the field of 
drug research were included in an iterative user-centred design 
process. User-centred design involves the user in the design 
process to ensure that the resulting product is understandable, 
usable and accomplishes the desired tasks [12]. Sedlmair et al. 
have proposed a methodological framework for design of a 
visualization that requires collaboration between the designer and 
user expert [8]. Three categories exist in the model: a precondition 
phase that describes what must be done before starting a design 
cycle; a core phase presenting the main steps of design; and an 
analysis phase depicting the analytical reasoning at the end.  This 
work aims to produce a validated visualization design and is thus 
is primarily concerned with the core phase of the design study 
comprising four stages: discover, design, implement, and deploy 
[8]. 
 
The first step in the core phase is discover: problem 
characterization and abstraction.  For this phase, we performed a 
detailed task analysis as part of a contextual enquiry [13], where 
an expert user was observed working in the laboratory and 
interrogated as necessary. 
 
The next three stages in the core phase are design, implement and 
deploy.  When the nature of the problem does not allow the 
designer to move with certainty from problem to solution, an 
iterative design process employing successive prototypes that are 
evaluated by the user is appropriate [9]. Such prototypes allow 
users to see and experience the system long before the final 
version is deployed. Our methodology incorporated four design-
implement-deploy iterations of increasing complexity, each of 
which involved user evaluation.  Details on each of the processes 
follow below. 
2.2.1 Discover  
The aim of the discover phase of data gathering and requirement 
analysis is to determine and clearly define the user requirements 
for the system being designed. The typical user profile for the 
system under design is a researcher in a drug screening facility 
investigating the efficacy and potency of a specific three-drug 
combination for treatment of TB. We used contextual inquiry − a 
semi-structured interview method that combines observation and 
interview − to gather information about the context of use [13]. 
This combination of structured queries with observation of the 
user reduces the possibility of omitting pertinent information [14]. 
 
The contextual enquiry took place in an MMRU research 
laboratory. The aim of this process was to understand the users 
requirements, the tasks they carry out and the environment in 
which they work. To gain further understanding of the tasks, the 
designer took the role of an experimenter: under the supervision 
of the expert user we conducted a three-drug combination assay 
experiment with a microplate reader and analysed the results, 
taking notes and asking questions during the process.  A non-
harmful bacterium, with similar behaviour to M. Tuberculosis, 
was used and known effective drugs were used as reagents. 
2.2.2 Design-Implement-Deploy Iterations  
Four iterations of the design process were conducted, with 
prototype implementations increasing in fidelity with each 
iteration. The design was thus refined progressively, which 
lessens the risk of over-committing to a design too early.  
The first two iterations were the simplest prototypes, the first a 
low-fidelity paper prototype and the second a simple interactive 
prototype. These prototypes were evaluated qualitatively, using 
the Wizard of Oz [15] and Think-out-loud [18] protocols 
respectively. User opinions were collected for both. Both of these 
prototypes used a synthetic data set.  
 
The third prototype was a high-fidelity implementation that used 
a real data set and served to test the accuracy of the system and its 
integration into the experimental process.  This prototype was 
evaluated with a questionnaire addressing usability and 
usefulness. 
 
The final iteration was used to address any outstanding issues 
with the system and was assessed with an expert evaluation and 
subsequent interviews. 
 
2.2.2.1 Iteration 1 
This iteration involved a low-fidelity paper prototype which was 
used to verify the tasks identified in the Discover phase and to 
reveal the methods of interaction the user employs to achieve the 
goals. The iteration developed multiple visualizations for each 
task and identified the methods of interaction that are most natural 
to the user. This is a rapid iteration intermediary between idea and 
implementation, allowing the system to be evaluated before too 
much time is consumed in development. 
The paper prototypes were hand-drawn mock-ups of the system 
design, which are inexpensive, easy to change and quick to 
complete. Rough sketches of the system were drawn on A4 paper, 
which represented the application window. The Wizard of Oz 
method was to evaluate these prototypes [15]. In this method, the 
user is presented with the mock-ups and allowed to “use” the 
prototype application as if it really existed by pressing on parts of 
the “screen” to mimic actions they would have done on a 
functioning machine [16].  
This iteration was tested with a combination of expert users who 
had knowledge of TB drug assays and non-expert users with 
knowledge of the TB drug discovery experimentation process. 
Expert user testing using Wizard of Oz is a way to clarify tasks 
and user requirements; while non-expert user testing validates that 
the tasks can be completed. Both sets of users reveal interaction 
methods that can be used in the development of the system.  
 
2.2.2.2 Iteration 2 
This iteration developed a simple, interactive prototype to ensure 
that the core functionality of the system could be implemented 
successfully.   The Think-Out-Aloud evaluation method was used 
to evaluate the prototype, where the users are encouraged to 
express their thoughts verbally and an observer records them [18]. 
The purpose of this qualitative evaluation was to identify the 
aspects that experts liked and disliked and what they found useful 
about the system.  A brief interview session was held after the 
user interacted with the system and the observer questioned the 
user on the actions they performed. This was done because most 
people find it difficult to act and speak at the same time.  As 
interactions were implemented, the system was also assessed for 
ease of interaction: the number of times the user asked a question 
was noted, and we also documented when they could not 
manipulate the system or were not able to perform a task.  
 
2.2.2.3 Iteration 3 
Iteration 3 refined the design and developed a full implementation 
of the visualization system: challenges and problems identified in 
Iteration 2 were addressed. This iteration was the first to use a real 
data set from a three-drug assay previously conducted. This 
iteration was evaluated both quantitatively and qualitatively with 
six users who all work in TB drug research. The users were given 
the system with the task of identifying the drug concentration 
combination that best inhibits the growth of the bacteria. Each 
user was observed as they used the system, the tasks performed 
were compared to the original tasks identified in the discover 
phase. In addition, the prototype was judged on its usability 
(effectiveness, efficiency, learnability and error prevention) and 
user experience (satisfaction and value).  The usability of the 
system was evaluated both through observation of the users, who 
were recorded on video as they interacted with the system, as well 
as with the widely used System Usability Scale (SUS) 
questionnaire [6]. SUS comprises ten statements, equally 
distributed between positive and negative, that are rated on a five-
point scale. The statements cover measures of effectiveness (the 
ability of the user to complete a task and the quality of the output 
of the task performed), efficiency (how long the user takes to 
complete the task and usefulness of the system) and satisfaction 
(subjective reactions of the user to using the system). The user 
(respondent) indicates the degree of agreement or disagreement 
with each statement. SUS has the advantage in that the final score 
is a single number between 0 to 100, which represents the 
composite measure of the usability of the system.  The SUS 
questionnaire has been found to be a robust measure of system 
usability even with a small sample size (as few as two users) [18]. 
To interpret the SUS score, we adopted the approach proposed by 
Bangor et al. [21]: the acceptability score is mapped to five 
descriptions,  “worst imaginable”, “poor”, “OK”, “good”, “best 
imaginable”.  
 
Table 1: Statements on usefulness, users indicate degree of 
agreement on a 5-point scale.  
1. This system enables me to accomplish tasks more quickly. 
2. This system supports critical aspects and answers critical 
questions. 
3. This allows me to accomplish more work than would 
otherwise be possible. 
4. Overall, I find this system useful. 
5. The system displays information in a logical order. 
6. The system highlights potentially effective drug combinations. 
7. I would recommend integration of this system with current TB 
drug discovery experimental methods. 
 
 
After assessing usability with the SUS, the usefulness of the 
system was also probed with seven statements aimed at 
determining whether they found the system to be useful and if 
they would recommend its use, as listed in Table 1. 
 
2.2.2.4 Iteration 4 
The final iteration of the project incorporated no new design 
ideas, but tested the system with real data and two expert users. 
The system was evaluated with a new data set obtained from the 
expert user and not previously analysed – the data set comprised 
results of the most recent experiment he had conducted.  In the 
expert evaluation process [18], one expert user was asked to 
analyse the data set with the visualization system and to draw 
conclusions, while another expert user analysed the same data set 
using the current manual methods. The conclusions were 
compared for similarity, and key values such as the FIC and MIC 
compared for accuracy.  
 
2.2.3 Evaluation Data 
The first two iterations validated design and feasibility 
respectively and were therefore tested with synthetic data 
resembling real data sets. These data sets were generated using a 
real data set as a template. The microplate reader measures 
absorbance between 20000 and 65000, and assigns values to a 12 
x 8 grid for each well. We used Microsoft Excel to generate 
random absorbances and concentration values in this grid.  
The final two iterations were tested with real data sets, 
representative of a single experiment and including drug names 
and concentrations and absorbance values (CSV) for each well on 
all five plates. The FIC, MIC and well-specific drug 
concentrations were collected and used to ensure that the data 
processing module produced accurate results. 
3. IMPLEMENTATION 
The visualization module takes as input (in CSV format) 
luminosity/absorbance values and initial concentrations of the 
drugs which the user inputs. The application has two aspects: data 
processing, which takes the user input and produces data in a 
suitable format for the visualisation, and a graphic representation 
aspect which produces images the user can interact with. 
 
The visualization tool in Iterations 3 and 4 was implemented in 
JavaScript to create a rapid prototype that could be hosted on a 
web page. The algorithms focused on ease of implementation, not 
efficiency: as the size of the input data set is relatively small, 
performance is not an issue. D3-js, a library for data driven 
applications, was used to visualize the plate data. Snap.svg, a 
JavaScript library for scalable vector graphics (SVG), was to 
show images. Interaction was implemented with jQuery. A Python 




The pre-condition phase of the design study (not discussed here) 
established the primary objective of the visualization tool as to aid 
in identifying promising drug combinations for further 
pharmacological development as a TB treatment.  The contextual 
enquiry in the Discover phase of this design study was used to 
elucidate the exact steps in the experimental procedure from 
which we abstracted the key sequence of events, as described 
below. 
4.1.1 Experimental procedure 
The assay experimental procedure places a combination of drugs 
and bacteria in each well of a 96 well plate at various 
concentrations. The bacteria are stained - interaction with the 
drugs results in a blue, pink or mixed colour change in the well. 
The colour intensity is measured using a microplate reader. A 




Figure 1: Schematic of the layout of a single microplate for a 3-drug TB assay. 
 
 
The wells in each plate are filled as shown in Figure 1. The first 
and last columns are culture (pink) and drug control (blue) 
respectively. In each plate, the cell A2 (red) is reserved for drug C 
alone, rows A3-A11 are reserved for Drug A alone and Drug B is 
placed in column B2-H2 (green). Drug A and B are two-fold 
diluted in each well, moving right across the columns (A) and 
down across the rows (B), with the maximum concentration of the 
drugs occurring in wells A3 and B2. Drug C increases in 
concentration from Plate 1 to Plate 5. The rows containing drugs 
alone enable MIC values for each drug to be calculated. Each 
column has a constant concentration of Drug A and each row has 
a constant concentration of Drug B. Drug C is added to the 
interacting region shaded lilac. 
 
On completion of the experiment, the researcher follows the 
procedure below for each plate. 
 
1. Determine the MIC of the drugs alone (MICAalone, 
MICBalone and MICalone). This is usually the concentration of 
the drug in the last well that has luminosity lower than the 
maximum. This is done by visual inspection of the microplate: the 
researcher judges where there is a colour change and concludes 
that the well before the colour change contains the MIC.  
 
2. Determine the MIC of the three drugs in combination. 
This is found in the shaded region (Figure 1), and is signified by 
the drug concentrations in the well that is not pink on the plate 
and has the lowest concentrations of drugs A and B.  
 
3. For each well in the interacting region, calculate the FIC  
values of the three drugs using the formula 𝐹𝐼𝐶 = (𝑐𝑜𝑛𝑐𝑒𝑡𝑟𝑎𝑡𝑖𝑜𝑛  𝑜𝑓  𝑑𝑟𝑢𝑔  𝑖𝑛  𝑤𝑒𝑙𝑙)/(𝑀𝐼𝐶  𝑜𝑓  𝑑𝑟𝑢𝑔) .  
 
4. For each well in the interacting region, determine the 
FIC index (FICI) using the formula: 𝐹𝐼𝐶𝐼 = 𝐹𝐼𝐶! + 𝐹𝐼𝐶! +𝐹𝐼𝐶! . 
  
5. Determine drug efficacy, measured by the 
absorbance/luminosity values produced by the microplate reader. 
Absorbance signifies the amount of bacteria growth in the well 
and can thus be manipulated into % inhibition. High values mean 
a large amount of bacteria and low values indicate high bacteria 
inhibition. The percentage inhibition is calculated using: 𝐿𝑢𝑚𝑖𝑛𝑜𝑠𝑖𝑡𝑦 = 𝑤𝑒𝑙𝑙 − 𝑎𝑣𝑒!"#$%"& 
 %𝑖𝑛ℎ𝑖𝑏𝑖𝑡𝑖𝑜𝑛 =    𝑙𝑢𝑚𝑖𝑛𝑜𝑠𝑖𝑡𝑦𝑎𝑣𝑒!"#$"%& − 𝑎𝑣𝑒!"#$%"& − 
  
6. Determine the lowest FICI that gives % Inhibition 
>90% and determine the synergy for that well. 
Synergy determination: 
FICI <= 0.75     Synergistic 
0.75>FICI<=4  no effect/additive effect  
FICI >4   Antagonistic 
 
A drug combination that is of interest has typically has the lowest 
FICI. However, for human treatment, another consideration is that 
the drug concentrations should also be relatively low, as, high 
concentrations can be harmful. 
 
4.1.2 Task analysis 
From the contextual enquiry, we identified the following sequence 
of events that an expert completes to determine if a candidate drug 
combination should be pursued further: 
1. Run the assay experiment and obtain absorbance values 
obtained for each well in the plate. Visually compare all the 
plates.  
In this task the user determines, by visual inspection of the plates, 
which plate appears to have promising results.  
 
2. Select a single plate for futher analysis.  
This process allows for analysis and data processing and has to be 
done for all the plates. 
 
3. Analyse the plate to determine the region of interaction, type 
of interaction, MIC, FIC and % Inhibition.  
This data is important because it helps the user determine whether 
the drug combination is to be investigated further. It is also a 
means for the user to gain a deeper understanding on the efficacy 
and potency of the drugs.  
 
4. Compare multiple plates to identify data points with 
synergistic interactions and high % inhibition.  
This task is the most important, as it determines which drug 
combination should be pursued for further development. With this 
information the user identifies the concentrations at which the 
drugs are most effective and how effective they are.  
This analysis revealed that a single graphical representation is 
unable to address each task because dependencies exist between 
them. As a result, each task is associated with its own design and 
the following interactions are employed to link the 
representations:  
• Select: mark something as interesting.  
• Explore: show something else.  
• Reconfigure: show a different arrangement.  
• Encode: show a different representation  
• Abstract/Elaborate: show more or less detail.  
• Filter: show something conditionally.  
 
During the task analysis, we identified only two misuse cases: an 
error with the experiment which requires the user to redo the 
experiment and the microplate producing faulty results which 
calls for the absorbance values to be re-measured or the 
experiment to do redone.  
 
4.1.3 Prototype architecture 
Task analysis enabled us to determine a suitable architecture for 
the software prototype, with the assumption that the user has setup 
identical to that used currently in the MMRU.  The architecture of 
the visualization module has three components: user input, data 
processing pipeline and data representation. 
 
First, the user inputs the initial concentration values for drugs A 
and B and the concentrations of drug C in each plate. This process 
aims to reduce the amount of work the user does before a 
graphical output is displayed. The user enters only the initial 
concentrations of the drugs and a twofold dilution for Drug A and 
B is assumed. Drug C concentrations are entered manually, as 





Figure 2: Paper Prototype design. (a) (Left) Start page for the Visual application. (Right) Main page of the visualisation, which 
serves as the home page where the user views an overview of the experiment. (b) A zoomed in plate view which appears when the 
user selects to view a single plate. (c) Graphic representation produced when multiple plates are selected simultaneously. 
 
Then the user then uploads a CSV file from the microplate reader 
containing luminosity/absorbance values. This raw data is 
processed in the processing module. Here, each well is assigned 




dilution, absorbance values from the CSV file, as well calculated 
FICI, MIC and % inhibition values (calculation details in 4.1).  In 
the step, the data is converted into a form suitable for the 
visualization. The % inhibition value for each well is calculated.   
 
The data is then passed to the visualisation system without the 
absorbance values, as they are not used in the graphic display. The 
visualisation data is an aggregate of five values (drug 
concentration, FICI, MIC and % inhibition) per well. The 
visualization system produces a graphic display of the data and 
allows the user to interact with it.  
4.2 Design Iteration 1 
In this first stage of our user-centred design process, we designed 
a rough paper prototype (Figure 2). In this mock-up, the main 
page view was chosen to be a flat structure instead of a 3D stack 
of the plates, because of the difficulty in viewing all plates in 3D.  
The microplates are each represented by an image glued onto the 
paper (Figure 2a). When a user selects a single plate (Figure 2b), 
the total number of synergistic and antagonistic interactions for 
each plate is plotted under each plate.  On the left, buttons allow 
the user to view synergistic interactions, antagonistic interactions 
or both. These regions can also be viewed on the plate, with 
different border highlights indicating different types of 
interaction. Luminosity/absorbance values are represented by the 
shading in each cell: a fully shaded cell represents 100% 
inhibition whereas a cell that is not shaded shows 0% inhibition. 
 
When multiple places are selected simultaneously (Figure 3c), the 
plates are arranged on the left hand side with a scatterplot of 
percentage inhibition versus FICI on the right. The scatterplot 
uses different shapes and colours for the data points of each plate, 
so that visual queries can be answered quickly: the user is able to 
link the shape and colour of a plot point to a given plate. Sliders 
on the x- and y-axis allow for filtering of the data points to reduce 
the amount of data shown at any moment. The pop-up shows the 
result of a user selecting a well. Users were asked to complete the 
following tasks on the paper prototype: 
1. Obtain an overview of the experimental results.  
2. View a single plate. Analyse the plate to determine the 
region of interaction and the type of interaction.  
3. Compare two or more plates.  
4. Determine the drug concentrations, MIC, FIC and % 
Inhibition values for any well in any plate.  
5. View data points that fall within the region of low FICI 
and high % inhibition.  
6. Establish which plate has the data point with the highest 
% inhibition and lowest FICI.  
Evaluation of the prototype revealed both good and bad design 
decisions and confirmed the sequence of the tasks. The first task 
required users to obtain an overview of the experiment; this was 
completed by submitting a user name, initial concentration values 
for each drug and uploading a CSV file with absorbance values on 
the start page. All participants were able to complete this activity 
easily.  Participants appreciated the fact that they could easily 
compare the number of good and bad interactions across all the 
plates, and that it allowed them make quick decisions about which 
plates are potential candidates. 
Task two, which required the participants to view a single plate 
for further analysis, revealed confusions around interaction with 
the system. Some users clicked the plate, some clicked the bar 
highlighting the number of interactions, while others were 
confused and asked the facilitator for help. 
 
Viewing different types of interactions was a challenging subtask 
for some of the participants, mainly because the paper prototype 
did not provide sufficient affordances. A number of participants 
did not see certain widgets as buttons, which made the execution 
of the given task difficult: they thought that they were labels 
(Figure 2b). 
 
For task 3, comparison of multiple plates (Figure 2c), we expected 
the user to go back to the home page and from there select more 
than one plate by clicking. However, this was not how the users 
attempted the task: the majority of them were unsuccessful at this 
activity. 
 
Paper prototypes, although cheap and quick, do not offer the same 
imagery that a computer based prototype does. Many times the 
users were unclear on whether certain widgets represented buttons 
or legend labels. We also identified affordances to add to the 
design, such as a “select all” button to allow the user to compare 
all the plates. The pop-up that appears when a well is selected was 
found to be restrictive, as only the one well’s data could be 
viewed at a given time. The placement and sizes of certain 
widgets, such as buttons, affected the user’s ability to perform 
certain tasks intuitively. The slider bars were found to be an 
effective filtering tool: expert users recommended the addition of 
slider bars for the drug concentrations. The expert users 
highlighted the importance of having a constant view of the plates 
throughout the analysis process. 
 
Testing with non-experts required the facilitator to explain the 
process more thoroughly and at times tasks could not be 
completed because the user did not have enough knowledge of the 
experimental procedure. Expert users were new to the concept of 
paper prototypes and often got caught up in details that did not 
pertain to the tasks they had to complete. This was both 
challenging and useful, it helped to get a better understanding of 
expectations, but at times the additions suggested were either 
beyond the scope of the project or too tailored to their specific 
experimental procedure. Overall testing with both experts and 
non-experts is beneficial to ensuring the correct level of usability 
and determining the accuracy and logic of the system before 
committing to a design. 
 
4.3 Design Iteration 2 
The paper prototype evaluation provided insights into strengths 
and weaknesses of the initial design. Design changes included 
implementing a static view of all the plates at the top of each 
page. Check boxes added to each plate enable selection of 
multiple plates. The option to select all or none was also added. 
Instead of the pop-up a table containing drug concentration, FIC 
index and luminosity values were placed below the plate 
representation when viewing a single plate and below the 
scatterplot when viewing multiple plates.  The table was placed at 
the bottom of the screen to provide more horizontal room for the 
plate, allowing each well to be larger and consequently easier to 
click. Also, the scroll wheel on mice make vertical scrolling easier 
than horizontal scrolling, which requires use of the browser’s 
scrollbars.  Sliders were added for the concentration values when 
multiple plates are selected (Figure 9) to allow the user to filter 
the data by concentration as well as luminosity and FIC index. 
The sliders are double sided so that the user can select a maximum 
and minimum value as they see fit. 
 
After making the necessary adjustments, a new prototype was 
tested with six users who had not seen the system before, so as to 
eliminate bias, as previous users may recall tasks and know what 
to do.  The users were able to complete all the tasks that were 
asked of them and did so with much more ease than before. The 
users liked that they could easily identify interesting data points. 
The detailed view of a single plate was found to be useful for 
exploring each plate individually and changing the type of 
interaction displayed at will. This indicates regions on the plate 
which revealed a trend to the user. The check boxes made it easier 
to select multiple plates and the users appreciated the ability to 
filter the scatter plot points using the sliders. A majority of the 
users requested that percentage inhibition be used instead of 
absorbance values, as this shows the potency of the drug 
combination more effectively without the user having to process 
the data any further. To aid the user visually it was recommended 
that the colours used for the data points on the scatter plot also be 
used to form a border around the plates they correspond to. This 
helps the user to make the relation between data point and plate. 
An additional feature that was added to the visualization enabled a 
data value on the table to be highlighted when a well is selected in 
the detailed view of the plate or a graph point in the scatter plot.  
 
This iteration helped to determine feasibility of the system design 
as well as improve the graphic representations. Testing using the 
Think-Out-Aloud protocol is effective if done well, the observer 
must be attentive so as not to miss any detail and the user 
sometimes requires encouragement to express their thoughts. 
Recording the evaluation procedure is beneficial and discussing 
the system with the user immediately after their interaction with it 
provides valuable information that could have been missed. 
 
4.4 Design Iteration 3 
In this iteration, the usability of a full prototype was tested.  Users 
were tasked to find the lowest drug concentration combination 
that interacts synergistically and inhibits the growth of bacteria, 
after which they completed the SUS questionnaire and questions 
on usefulness.  Interestingly, although all the users managed to 
complete this single task successfully, they used a variety of 
different steps to do so.  This illustrates the inherent exploratory 
nature of drug candidate identification. The SUS scores listed in 
Table 2 indicates that the system is acceptable in terms of 
usability: the score of 72.5 corresponds to a rating of 'good' and 
the highest of 95.5 is “excellent”.  All six users strongly agreed on 
the ability of the system to help them conclude if a candidate drug 
combination should be pursued for further study. The users also 
indicated that the system would allow them to accomplish the 
analysis task more quickly and that they would recommend the 
use of the system. The users comments highlighted the positive 
aspects of the design as well as possible improvements.   The 
mapping of the microplates was a primary concern for users. A 
good mapping affords clarity and ease of use allowing the user to 
rely on recognition rather than recall. Users suggested changing 
the ID values of the data points in the table to indicate row and 
column so that the user could easily pick out the corresponding 
well; this is the conventional way of labelling a microplate.  In 
addition, the random colours used for the well concentrations 
confused many users. It was recommended that the wells take on 
the conventional blue, purple or pink colours, which correspond to 
growth, some growth and no growth of bacteria.  Both of these 
suggestions were implemented in the final iteration. 
 
Table 2: Converted user responses for each statement and 
final SUS Score for each user calculated as follows:  
Odd statement= (User Response -1) and Even number 
statement = (5-User Response)  
   User User User User User User 
        
Statement 1  4 4 4 4 4 3 
Statement 2  3 4 3 3 4 3 
        
Statement 3  4 3 3 3 4 3 
Statement 4  3 3 3 3 3 3 
        
Statement 5  3 3 3 3 4 3 
Statement 6  3 3 3 3 4 3 
        
Statement 7  3 4 3 2 3 3 
Statement 8  4 3 3 3 4 3 
        
Statement 9  3 3 3 3 4 3 
Statement 10  3 3 3 2 4 3 
         
Sum of Converted 33 33 31 29 38 30 
Overall Score = Sum * 82.5 82.5 77.5 72.5 95 75 
         
 
4.5 Design Iteration 4 
This final iteration ensured precision (a key concern for 
researchers) and robustness. Minor changes also were made to the 
design (Figure 3), principally involving alterations to make the 
representation of the microplates as close as possible to the real 
microplates.  A single plate is represented as a 2D array which 
akin to the grid structure of a plate (Figure 3a). Each element 
represents a well in a plate consisting of percentage inhibition, 
drug concentrations and FICI values. The well colours were 
changed to blue, purple and pink, according to the percentage 
inhibition value for each well. Blue represents inhibition greater 
than 90%, purple inhibition between 90%-50% and pink 
inhibition less than 50%. Comparison of two or more plates 
creates a scatter plot of percentage inhibition vs FICI (Figure 3b).  
 
The evaluation of this final system with two experts confirmed 
that our visualisation tool was able to produce the same results as 
those obtained using manual methods. The only clear difference 
was that manual methods give a range for MIC values. Manual 
methods rely on human vision to differentiate a colour change 
from blue to pink; if the researcher cannot distinguish when 
exactly the colour change took place they give a maximum and 
minimum concentration value. The true MIC lies within that given 
range. Our system uses percentage inhibition values and can 
therefore pick out the exact MIC based on the last well in the row 





Figure 3: Final Visualisation Design. (a) Display when a single microplate is selected.  The overview of all plates in the experiment 
is shown at the top. (b) Graphic representation produced when multiple plates are selected simultaneously, showing the scatterplot 
of % Inhibition versus FIC index values for the plates selected. A set of sliders on the left allows users to filter the scatterplot. 
 
The final questionnaire evaluation with two experts had extremely 
positive ratings for both usability (extremely and usefulness.  
Most importantly, comments indicated that the tool would both 
reduce time and be helpful for identification. 
 
5. DISCUSSION AND REFLECTION 
This design study benefitted to a large degree from a user-centred 
methodology we employed involving domain experts in the 
design: because of the complexity of the drug screening data set 
and the very specific requirements of the researchers, it would 
have been very difficult to come up with an effective design 
without their direct involvement. However, difficulties arose in 
involving active researchers in the design cycle, as this required a 
time commitment, which they initially underestimated.   To 
prevent delays in the design cycle, we had to work around the 
users’ very full and rather inflexible time schedules. 
 
In this study, our initial contextual inquiry involved both 
interviews and careful observation of an actual drug screening 
experiment.  This detailed process was very useful for acquiring 
insight into the complex tasks and processes researchers perform 
when analysing a drug screening experiment.  It also helped to 
clarify the specific data analysis challenges faced by the 
researchers.  
 
The initial low-fidelity prototypes allowed for evaluating 
speculative techniques and mechanisms without the time and cost 
of implementing them. This method was effective because the 
ideas were not influenced by the designers’ capabilities or 
programming knowledge. However, the Wizard of Oz evaluation 
of the non-functional prototype was unexpectedly challenging and 
time-consuming with users very familiar with paper-prototypes. 
We found that the combination of expert and non-expert testing to 
be beneficial.  While non-experts may find a complex system 
confusing, experts may be too invested in the outcome to be 
sufficiently critical of the initial designs. We found that our expert 
users appreciated many of the changes that were made based on 
evaluations with non-experts. 
 
Overall, we found that the incremental build process involving 
four design iterations was very useful in that large changes to the 
design suggested by the user evaluations were easily addressed in 
(a) 
(b) 
the early stages before actual implementation.  This was 
particularly useful in the process of refining what was to be 
implemented, as we avoided addressing technical details of the 
non-functional requirements.  In addition, we discovered that 
users found a close mapping of the data images to the actual 
laboratory microplates to be helpful.  This suggests a general 
design heuristic for scientific visualization: where possible, to 
facilitate user recognition rather than recall, images or 
representations that map to familiar laboratory equipment or 
processes should be used. 
 
The ultimate goal of our study was design of a data set 
visualization that aids in identifying promising drug candidates. 
Our qualitative final evaluation suggests that our design will assist 
in more rapidly identifying promising drug combinations. 
However, as there is no other visualization system to which expert 
users’ could compare our design, the results of the evaluation may 
not be an accurate reflection of the effectiveness of our design, but 
rather enthusiasm for automation. Testing the system with more 
users and comparing it to other visualization tools would be 
beneficial to revealing the true usefulness of the system. Further, 
because of the exploratory nature of drug discovery research, it is 
difficult to measure success on this relatively short time scale and 
to what extent it really meets the requirements of drug 
researchers.  
 
6. CONCLUSIONS AND FUTURE WORK 
This study produced an effective design of a visualization tool to 
facilitate evaluation of the data from assays of three-drug 
combinations against tuberculosis in order to identify promising 
drug combinations. Our methodology combining an initial 
detailed contextual enquiry with an iterative user-centred design 
process ensured that not only was the project completed on time 
with all features and functions as initially specified but also that 
the system was usable.  
Future work will involve a full implementation of the design with 
subsequent longitudinal testing.  
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